|
Oct 4
|
Sage stock slides as RBC cuts rating to Sell on trial results concerns
|
|
Sep 29
|
Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now
|
|
Sep 27
|
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
|
|
Sep 27
|
SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
|
|
Sep 26
|
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|
|
Sep 26
|
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
|
|
Sep 25
|
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers
|
|
Aug 30
|
Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?
|
|
Jul 31
|
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
|
|
Jul 31
|
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
|
|
Jul 30
|
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
|
|
Jul 26
|
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
|
Jul 25
|
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 25
|
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
|
|
Jul 24
|
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
|
|
Jul 24
|
Sage Therapeutics Stock Slides as Pipeline Thins
|
|
Jul 24
|
Biogen, Sage tremor drug fails key trial
|
|
Jul 24
|
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
|
|
Jun 12
|
SAGE's Huntington's Disease Study Meets Primary Endpoint
|
|
Jun 11
|
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
|